Sanjay P. Bagaria, M.D., studies the molecular characteristics of sarcoma, melanoma and breast cancer. The long-term goal of Dr. Bagaria's research is to develop a method to predict response to therapy for sarcoma, melanoma and breast cancer.
Dr. Bagaria's team has conducted extensive research using gene expression analysis, in vitro and in vivo assays, and clinical samples to identify, determine the significance of and validate the predictive value of novel biomarkers.
- Developing a molecular classification system for soft tissue sarcoma. Soft tissue sarcomas vary widely in histology and prognosis. Dr. Bagaria's team is working to better understand the molecular characteristics of soft tissue sarcoma, which would allow for a more standard classification system and ultimately make it possible to provide therapy targeted to each specific sarcoma.
- Predicting the likelihood of developing breast cancer in BRCA carriers. BRCA breast cancer patients have a genetic mutation that predisposes them to developing breast cancer. Dr. Bagaria's team is developing a biomarker assay that exploits the BRCA mutation to identify those patients at an increased risk of developing breast cancer.
- Understanding the factors that result in metastasis from melanoma. Dr. Bagaria's team is interested in examining the factors that are associated with melanoma's ability to spread.
Significance to patient care
Current cancer treatment recommendations are based on the size of the tumor, status of lymph nodes and presence of distant disease. With his research, Dr. Bagaria hopes to add a biological component to the understanding of sarcoma, melanoma and breast cancer.
This would allow clinicians and scientists to better define these cancers, predict their prognosis and ultimately provide effective, targeted therapies.